The EC has granted expanded approval to BMS' Breyanzi, to treat adults with relapsed or refractory follicular lymphoma (FL).

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

A potential rally to 6,000 is possible if retail sales are positive and the FOMC Meeting is dovish. Read why investors should ...

John Vaughan, a dedicated leader at Verily Life Sciences LLC, serves in multiple roles including lead product counsel, ...

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how competitive Abecma will continue to be in the multiple myeloma space given an ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other Friday’s worst performing stocks. Wall Street’s main indices bounced back on Friday, ...

The S&P 500 jumped 2.1% on Friday, March 14, wrapping up a volatile week as government shutdown concerns eased.

EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...

K reports of America’s largest pharmaceutical companies show that they continue to avoid paying much, if any, U.S. corporate income tax.

The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.